How Changes in the IPR Environment in the Indian Pharmaceutical Sector Affect the Business Models of Multinational Enterprises?
Authors
Buraja, Jekaterina ; Staneva, Teodora
Term
4. term
Publication year
2016
Submitted on
2016-06-08
Pages
115
Abstract
Dette speciale undersøger, hvordan ændringer i rammerne for intellektuelle ejendomsrettigheder (IPR) i den indiske lægemiddelsektor påvirker multinationale virksomheders (MNE'ers) forretningsmodeller. Afhandlingen behandler også den grundlæggende afvejning mellem samfundsmæssig velfærd og incitamenter til innovation. For at besvare spørgsmålet udvikles en ramme, der forbinder innovationssystemer (nationale og sektorspecifikke), IPR, åben innovation (samarbejde og videndeling på tværs af organisatoriske grænser) og forretningsmodeller (hvordan virksomheder skaber og indfanger værdi). Tre sager, hvor MNE'er tabte patentsager i Indien, analyseres ved hjælp af Yins single embedded case study-tilgang, en struktureret casestudie-metode. Resultaterne viser, at ændringer i Indiens IPR-regler får udenlandske og indenlandske MNE'er til at tilpasse deres forretningsmodeller på forskellige måder. Den centrale implikation er, at udviklingslande bør tilpasse deres institutionelle rammer til globale IPR-standarder uden at tilsidesætte egne økonomiske og sociale hensyn. For at styrke pålideligheden er der behov for flere casestudier fra udviklingslande, og fremtidig forskning kan undersøge nye forretningsmodeller i lægemiddelsektoren, der bedre balancerer samfundshensyn og incitamenter til opfindelser.
This thesis examines how changes in India’s intellectual property rights (IPR) environment influence the business models of multinational enterprises (MNEs) in the pharmaceutical sector, while also considering the broader trade-off between social welfare and incentives for innovation. To address these questions, the study develops a framework that links innovation systems (national and sectoral), IPR, open innovation (collaboration and knowledge sharing across organizational boundaries), and business models (how firms create and capture value). It analyzes three cases in which MNEs lost patent disputes in India, using Yin’s single embedded case study approach, a structured case study design. The findings show that shifts in India’s IPR rules prompt foreign and domestic MNEs to adjust their business models in different ways. The key implication is that developing countries should adapt their institutions to align with global IPR standards without sacrificing their own economic and social interests. To strengthen reliability, more case studies from developing countries are needed, and future research could explore new pharmaceutical business models that better balance public welfare and incentives for invention.
[This abstract was generated with the help of AI]
Keywords
Documents